{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:06:31Z","timestamp":1789139191031,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020372","name":"Shanghai Junshi Biosciences Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020372","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.atherosclerosis.2025.120408","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T07:21:10Z","timestamp":1750058470000},"page":"120408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial"],"prefix":"10.1016","volume":"407","author":[{"given":"Chunli","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaopin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-803X","authenticated-orcid":false,"given":"Yi-da","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2025.120408_bib1","first-page":"e285\u2043e350","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2025.120408_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2025.120408_bib3","first-page":"237","article-title":"Joint committee on the Chinese guidelines for lipid management. Chinese guidelines for lipid management","volume":"38","year":"2023","journal-title":"Chin J Cardiol"},{"issue":"34","key":"10.1016\/j.atherosclerosis.2025.120408_bib4","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120408_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5551\/jat.RV16004","article-title":"Racial differences in the cholesterol-lowering effect of statin","volume":"24","author":"Naito","year":"2017","journal-title":"J Atherosclerosis Thromb"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2025.120408_bib6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120408_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.amjcard.2007.09.096","article-title":"Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients","volume":"101","author":"Athyros","year":"2008","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2025.120408_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"issue":"18","key":"10.1016\/j.atherosclerosis.2025.120408_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2025.120408_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2025.120408_bib11","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a Statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2025.120408_bib12","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2025.120408_bib13","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"GAUSS-3 investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related Statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2025.120408_bib14","article-title":"Efficacy and safety of ongericimab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia","author":"Wang","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2025.120408_bib15","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"33","key":"10.1016\/j.atherosclerosis.2025.120408_bib16","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.2174\/138161211798220891","article-title":"Statin discontinuation in high-risk patients: a systematic review of the evidence","volume":"17","author":"Gomez","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2025.120408_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100669","article-title":"Sex differences in cardiovascular outcomes and cholesterol-lowering efficacy of PCSK9 inhibitors: systematic review and meta-analysis","volume":"28","author":"Rivera","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.atherosclerosis.2025.120408_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2020.07.014","article-title":"IMPROVE study group. Sex-specific predictors of PCSK9 levels in a European population: the IMPROVE study","volume":"309","author":"Ferri","year":"2020","journal-title":"Atherosclerosis"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915025013061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:08:38Z","timestamp":1778944118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915025013061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"alternative-id":["S0021915025013061"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120408","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120408"}}